BRAF mutation testing with a rapid, fully integrated molecular diagnostics system

Oncotarget

Volumn 6, Issue 29, 2015, Pages 26886-26894

  Janku, Filip ^a   Claes, Bart ^b   Huang, Helen J ^a   Falchook, Gerald S ^a,c   Devogelaere, Benoit ^b,e   Kockx, Mark ^f   Bempt, Isabelle Vanden ^f   Reijans, Martin ^b   Naing, Aung ^a   Fu, Siqing ^a   Piha Paul, Sarina A ^a   Hong, David S ^a   Holley, Veronica R ^a   Tsimberidou, Apostolia M ^a   Stepanek, Vanda M ^a   Patel, Sapna P ^a   Kopetz, E Scott ^a   Subbiah, Vivek ^a   Wheler, Jennifer J ^a   Zinner, Ralph G ^a   Karp, Daniel D ^a   Luthra, Rajyalakshmi ^a   Roy Chowdhuri, Sinchita ^a   Sablon, Erwin ^b   Meric Bernstam, Funda ^a   Maertens, Geert ^b   Kurzrock, Razelle ^a,d   more..

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b Biocartis SA   (Belgium)

^c HealthOne   (United States)

^d UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^e Cartagenia   (Belgium)

^f HistoGeneX NV   (Belgium)

Author keywords

BRAF; Integrated; qPCR; Rapid

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; FORMALDEHYDE; PARAFFIN;

ARTICLE; BRAF GENE; CONTROLLED STUDY; GENE MUTATION; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; MOLECULAR DIAGNOSTICS; MUTATIONAL ANALYSIS; NEOPLASM; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; RAPID TEST; SENSITIVITY AND SPECIFICITY; CHEMISTRY; DNA MUTATIONAL ANALYSIS; GENETICS; HIGH THROUGHPUT SEQUENCING; MELANOMA; METABOLISM; MOLECULAR PATHOLOGY; MUTATION; NEOPLASMS; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY; SKIN NEOPLASMS;

DNA MUTATIONAL ANALYSIS; FORMALDEHYDE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; MELANOMA; MUTATION; NEOPLASMS; PARAFFIN EMBEDDING; PATHOLOGY, MOLECULAR; PROTO-ONCOGENE PROTEINS B-RAF; REAL-TIME POLYMERASE CHAIN REACTION; REPRODUCIBILITY OF RESULTS; SKIN NEOPLASMS;

EID: 84944463600     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.4723     Document Type: Article

References (15)

1. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, et al. Efficacy and safety of a specific inhibitor of the bcr-abl tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344:1031-7.
2. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350:2129-39.
3. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010; 363:1693-703.
4. Falchook GS, Long GV, Kurzrock R, Kim KB, Arkenau TH, Brown MP, et al. Dabrafenib in patients with melanoma, untreated brain metastases, and other solid tumours: A phase 1 dose-escalation trial. Lancet. 2012; 379:1893-901.
5. Flaherty KT, Puzanov I, Kim KB, Ribas A, McArthur GA, Sosman JA, et al. Inhibition of mutated, activated braf in metastatic melanoma. N Engl J Med. 2010; 363:809-19.
6. Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, et al. Assessing pik3ca and pten in earlyphase trials with pi3k/akt/mtor inhibitors. Cell Rep. 2014; 6:377-87.
7. Peters S, Michielin O, Zimmermann S. Dramatic response induced by vemurafenib in a braf v600e-mutated lung adenocarcinoma. J Clin Oncol. 2013; 31:e341-4.
8. Munoz J, Schlette E, Kurzrock R. Rapid response to vemurafenib in a heavily pretreated patient with hairy cell leukemia and a braf mutation. J Clin Oncol. 2013; 31:e351-2.
9. Hyman DM, Diamond EL, Vibat CR, Hassaine L, Poole JC, Patel M, et al. Prospective blinded study of brafv600e mutation detection in cell-free DNA of patients with systemic histiocytic disorders. Cancer Discov. 2014.
10. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with braf v600e mutation. N Engl J Med. 2011; 364:2507-16.
11. Sam SS, Lebel KA, Bissaillon CL, Tafe LJ, Tsongalis GJ, Lefferts JA. Automation of genomic DNA isolation from formalin-fixed, paraffin-embedded tissues. Pathol Res Pract. 2012; 208:705-7.
12. Roychowdhury S, Iyer MK, Robinson DR, Lonigro RJ, Wu YM, Cao X, et al. Personalized oncology through integrative high-throughput sequencing: A pilot study. Sci Transl Med. 2011; 3:111ra21.
13. Hatzivassiliou G, Song K, Yen I, Brandhuber BJ, Anderson DJ, Alvarado R, et al. Raf inhibitors prime wildtype raf to activate the mapk pathway and enhance growth. Nature. 2010; 464:431-5.
14. Yancovitz M, Litterman A, Yoon J, Ng E, Shapiro RL, Berman RS, et al. Intra-and inter-tumor heterogeneity of braf(v600e) mutations in primary and metastatic melanoma. PLoS One. 2012; 7:e29336.
15. Klein O, Clements A, Menzies AM, O'Toole S, Kefford RF, Long GV. Braf inhibitor activity in v600r metastatic melanoma. Eur J Cancer. 2013; 49:1073-9.